ABSTRACT
The Pittsburgh Sleep Quality Index (PSQI) is a self-reported questionnaire evaluating sleep quality based on seven domains of sleep disorders. However, the factor structure of PSQI needs to be well-established among medical students. This study was conducted to establish the factor structure of PSQI among medical students. Four-hundred and four medical students completed the PSQI. Considering each PSQI component as an "observed variable," exploratory factor analysis was conducted. Six models explaining the factor structure of PSQI were compared by confirmatory factor analysis to achieve the best model. All PSQI components were loaded on three factors. The first factor included sleep duration and habitual sleep efficiency, the second was subjective sleep quality and sleep latency, and the third was sleep disturbances, sleeping medications, and daytime dysfunction (root mean square error of approximation = < 0.01, goodness of fit index = 0.99). The differences in Bayesian information criteria and root mean square error of approximation between our best-fit model and each of the other resulted in rejection of all other Models. Besides confirming the structural validity among medical students, our findings indicated the adequacy of the 3-factor structure of PSQI, including sleep efficiency, perceived sleep quality, and daily disturbances in this population.
Subject(s)
Sleep Wake Disorders , Students, Medical , Humans , Sleep Quality , Iran , Bayes Theorem , Reproducibility of Results , Surveys and Questionnaires , Sleep , Sleep Wake Disorders/diagnosis , Sleep Wake Disorders/epidemiologyABSTRACT
INTRODUCTION: In the present study, we have examined different aspects and potentials of stem cells for the management of patients infected with COVID-19. BACKGROUND: The novel coronavirus disease (COVID-19) has been reported in most of the countries and territories (>230) of the world with .686 million confirmed cases (as of Apr. 22, 2023). While the scientific community is working to develop vaccines and develop drugs against the COVID-19 pandemic, novel alternative therapies may reduce the mortality rate. Recently, the application of stem cells for critically ill COVID-19 patients in a small group of patients has been examined. METHODS: We searched PubMed, Web of Science, and Google Scholar up to July 2022. Those studies that reviewed COVID-19 and cell therapy potentials were entered into the study. Moreover, some recently published patents were exploited and reviewed. Patentscope, USPTO, Espacenet, Free Patents Online, and Google Patents were used for patent searches. RESULTS: Cell-based therapy as a modality of regenerative medicine is considered one of the most promising disciplines in the fields of modern science and medicine. Such an advanced technology offers endless possibilities for transformative and potentially curative treatments for some of the most life-threatening diseases. This therapeutic tool can be useful to reduce the rate of mortality. There have been several published patents for different stem cell therapy platforms in recent years. CONCLUSION: Stem cell therapy could be considered a safe and effective therapeutic strategy to reduce death cases in patients infected with COVID-19. Besides, stem cell therapy might increase the pulmonary functions in the patients, it suppresses the occurring inflammations and ameliorates the symptoms.
Subject(s)
COVID-19 , Humans , COVID-19/therapy , Pandemics , Patents as Topic , SARS-CoV-2 , Cell- and Tissue-Based TherapyABSTRACT
BACKGROUND: Vitamin D, one of the most essential micronutrients, is crucial in various health outcomes. However, previous studies showed conflicting results and uncertainty about vitamin D supplementation's optimal dosage and duration. In this study, we aimed to evaluate the vitamin D supplements efficiency on serum levels of 25-hydroxy vitamin D (25(OH)D), 1,25-dihdroxy vitamin D (1,25(OH)2D), parathyroid hormone (PTH) and renin-angiotensin-aldosterone system (RAAS) in adults. METHODS: A systematic analysis of eligible and relevant randomized-controlled trials (RCT) published before April 2023 assessing the effect of vitamin D supplementations applied. The studies were identified by searching several databases, including Pubmed, Scopus, Web of Science, ProQuest, and Cochrane Register of controlled trials. RESULTS: Five eligible RCTs with 346 participants in the intervention and 352 participants in the control group were assessed in our project. According to the results, there was a substantial change in 25(OH)D (SMD: 2.2, I2: 92.3, 95% Confidence Interval (CI): 1.38-3.02, P-value: 0.048) and 1,25(OH)2D (SMD:1.23, I2: 86.3, 95% CI: 0.01- 2.44, P-value < 0.010) affected by vitamin D intervention. Regarding Parathyroid hormone (PTH), however, vitamin D intervention showed a remarkable decrease (SMD: -0.75, I2: 82.4, 95% CI: (-1.3)-(-0.18), P-value < 0.010). Moreover, sensitivity analysis showed significant publication bias in terms of 25(OH)D. CONCLUSION: Vitamin D supplements significantly increase the serum levels of 25(OH)D and 1,25(OH)2D and decrease PTH levels. While some studies reported decreasing effect of vitamin D supplements on RAAS activity, some reported no changes.
ABSTRACT
Background There are considerable differences in the prevalence of coronary artery disease (CAD) and its cardiovascular risk factors between men and women. Due to the significance of gender as a factor that potentially affects cardiovascular disorders and patient outcomes, the present study aimed to assess the baseline characteristics and outcomes of CAD patients in terms of gender distribution. Methods All consecutive patients diagnosed with ST-elevation myocardial infarction (MI) who had undergone primary percutaneous coronary intervention (PCI) in the previous two years in a comprehensive cardiology center were included. Data were retrospectively collected from the hospital record files. Color Doppler echocardiography, valvular involvement, and the type of coronary vessel involvement were also evaluated. Results In total, 557 consecutive patients (437 men and 120 women) were included with a mean age of 59.37 ± 26.23 years and 64.07 ± 11.60 years for men and women, respectively (p = 0.004). The prevalence of mitral regurgitation (MR) and tricuspid regurgitation (TR) was significantly higher among women than men. Conclusion Female patients who suffered from CAD and underwent PCI were older than men. Also, ischemic mitral regurgitation (MR) and tricuspid regurgitation (TR) were more prevalent among women, while smoking was more prevalent among men.
